Pharma company reaches $2.2B settlement in Zantac lawsuits
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer,
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was contaminated with a suspected carcinogen.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer.
The company also agreed to pay $70 million to settle a whistleblower lawsuit
GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer.
GSK says $2.2bn settlement resolves most Zantac litigation
GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the settlements, which will be funded through "existing resources," and said there will be "no changes to GSK's growth agenda or investment plans for R&D as a result."
GSK Settles Zantac Lawsuits: A New Chapter for the Controversial Drug
The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that certain versions might contain impurities linked to cancer,
GSK shares jump after settlement of 80,000 Zantac lawsuits in U.S
(Reuters) -Shares of GSK rose 6% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer.
pharmaphorum4y
FDA says all ranitidine drugs should be recalled on safety concerns
The FDA has asked drugmakers to pull all prescription and over-the-counter products based on ranitidine off the market immediately, after a review failed to alleviate concerns about a cancer risk.
Buy1d
TOP NEWS: GSK to settle 80,000 Zantac cases for up to USD2.2 billion
(Alliance News) - GSK PLC on Wednesday agreed to pay up to USD2.2 billion to settle the vast majority of cases linked to its heartburn medicine Zantac.
The Pharma Letter16h
End in sight for GSK's Zantac woes, with $2.2 billion deal
GSK (LSE: GSK) has settled 93% of Zantac (ranitidine) product liability cases in the USA, agreeing to pay up to $2.2 billion ...